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Objectives. Elevated levels of serum homocysteine (Hcy) have been associated with cardiovascular diseases and endothelial
dysfunction, conditions closely associated with erectile dysfunction (ED). This meta-analysis was aimed to assess serum Hcy
levels in subjects with ED compared to controls in order to clarify the role of Hcy in the pathogenesis of ED. Methods. Medline,
Embase, and the Cochrane Library were searched for publications investigating the possible association between ED and Hcy.
Results were restricted by language, but no time restriction was applied. Standardized mean difference (SMD) was obtained by
random effect models. Results. A total of 9 studies were included in the analysis with a total of 1320 subjects (489 subjects with
ED; 831 subjects without ED). Pooled estimate was in favor of increased Hcy in subjects with ED with a SMD of 1.00, 95% CI
0.65–1.35, p < 0 0001. Subgroup analysis based on prevalence of diabetes showed significantly higher SMD in subjects without
diabetes (1.34 (95% CI 1.08–1.60)) compared to subjects with diabetes (0.68 (95% CI 0.39–0.97), p < 0 0025 versus subgroup w/o
diabetes). Conclusions. Results from our meta-analysis suggest that increased levels of serum Hcy are more often observed in
subjects with ED; however, increase in Hcy is less evident in diabetic compared to nondiabetic subjects. This study is registered
with Prospero registration number CRD42018087558.
1. Introduction
Prevalence of erectile disorders increases steadily with aging,
from 1 to 10% in men younger than 40 years up to 70–100%
in men older than 70 years [1, 2]. It is widely accepted that
several factorsmight be involved in thepathogenesis of erectile
dysfunction (ED): guidelines suggest investigating organic
causes [3], such as endocrine alterations [4, 5], neurological
impairment [1, 6], and vascular dysfunction [6] as well
as psychological or relational issues [7, 8].
However, given the importance of hemodynamics in
allowing adequate erection, it should come as no surprise that
ED shares the same risk factors of many cardiovascular (CV)
affections [9].
In these regards, hyperhomocysteinemia (HHcy) has
sprung into attention for its involvement in endothelial
dysfunction [10]. Several meta-analysis studies have con-
firmed the association with consistently elevated levels of
homocysteine (Hcy) and the risk of CV diseases: Boushey
and colleagues [11] reported a 1.6 OR (95% CI 1.4–1.7)
for coronary artery disease in men following an increase of
5μmol/l in serum Hcy levels, whereas Clarke et al. [12]
described that a reduction of 25% of serum Hcy was associ-
ated with an 11% lower risk of ischemic heart disease and
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with a ~20% lower risk of stroke. However, other reports have
suggested that Hcy lowering interventions do not prevent CV
events [13], or that Hcy is a marker of unhealthy lifestyles
[14], thus being indirectly associated with CV health.
Despite the prevalence of ED and its known association
with endothelial dysfunction [15, 16], its link with serum
Hcy has not been adequately addressed. HHcy is associated
with increased arterial stiffness [17] and with impaired nitric
oxide synthase activity [18]. Several studies have assessed
whether subjects suffering from ED have increased serum
Hcy compared to controls, but most of these studies have
been performed in small populations and generally do not
provide solid evidence in these regards.
2. Materials and Methods
2.1. Methods. This meta-analysis was performed in line with
the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) reporting guideline [19] (see Supple-
mentary file 1). The protocol of this study (CRD42018087558)
was published on the website of the University of York
(Centre for Reviews and Dissemination) and can be accessed
at the following address: http://www.crd.york.ac.uk/PROS
PERO/display_record.php?ID=CRD42018087558.
2.2. Search Strategy. An extensive Medline, Embase, and
Cochrane search was performed, including the following
words: (“erectile dysfunction”[MeSH Terms] OR (“erecti-
le”[All Fields] AND “dysfunction”[All Fields]) OR “erectile
dysfunction”[All Fields]) OR ((“penile erection”[MeSH
Terms] OR (“penile”[All Fields] AND “erection”[All Fields])
OR “penile erection”[All Fields] OR “erectile”[All Fields])
AND(“physiology”[Subheading]OR “physiology”[All Fields]
OR “function”[AllFields]OR “physiology”[MeSHTerms]OR
“function”[All Fields])) OR ((“sexual behavior”[MeSH
Terms]OR (“sexual”[All Fields] AND “behavior”[All Fields])
OR “sexual behavior”[All Fields] OR “sexual”[All Fields])
AND (“physiopathology”[Subheading] OR “physiopatholo-
gy”[All Fields] OR “dysfunction”[All Fields])) AND (“homo-
cysteine”[MeSH Terms] OR “homocysteine”[All Fields]).
The search, which accrued data up to February 28th 2018,
was restricted to articles written in English, Italian, or French
and studies including human participants. The identification
of relevant studies was performed independently by two of
the authors (SA and SM), and conflicts were resolved by a
different investigator (CA). We did not employ search soft-
ware but hand-searched bibliographies of retrieved papers
for additional references. The main source of information
was derived from published articles.
2.3. Study Selection. All studies reporting serum Hcy levels in
patients with ED and control population were included. Case
reports were excluded from the analysis (see Figure 1).
2.4. Outcome and Quality Assessment. The principal outcome
was the serum concentration of Hcy in subjects with and
without erectile dysfunction. The quality of studies included
was assessed using the Cochrane criteria [20]. Difference in
Hcy levels between subjects with and without ED was
measured with standardized mean difference (SMD) as
Initial results from research
n = 30
Records after duplicates removed
n = 30
Records screened
n = 30
Records assessed for eligibility
n = 16
Studies included in meta-analysis
n = 9
Records excluded
No full text = 2
Animal study = 5
Case reports = 2
Reviews = 4
Editorial = 1
Records excluded
Study design = 7
Figure 1: Flowchart detailing all phases of data retrieval.
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different kits and tools have been used in different studies
(Table 1). All measures of ED were included in the analy-
sis, including the International Index of Erectile Function
(IIEF), a 15-item questionnaire extensively used for clinical
and research purposes [21], and its abridged, 5-item ver-
sion (IIEF-5) [22], as well as assessment of ED by means
of a single question.
2.5. Statistical Analysis. Data from retrieved study were
extracted and entered twice by two authors (SA and CA) into
two separate standard Excel templates which were then
cross-checked by the other author. Extracted data included
data sources, eligibility, methods, participant characteristics,
and results. Heterogeneity in serum Hcy levels was assessed
using I2 statistics. Even when low heterogeneity was detected,
a random effect model was applied, because the validity of
tests of heterogeneity can be limited with a small number of
component studies. We used funnel plots and the Begg
adjusted rank correlation test to estimate possible publication
or disclosure bias (Begg et al., 1994); however, undetected
bias may still be present because these tests have low sta-
tistical power when the number of trials is small. Statistical
analysis was performed independently by two authors (SA
and CA) with the meta package on the statistical software
R (version 3.4.2) [23].
3. Results
Out of 30 retrieved articles, 9 were included in the study
(Table 1). The study flow is summarized in Figure 1. The
characteristics of the retrieved studies, including assess-
ment of their overall quality, are reported in Table 1 and
Supplementary file 1. Retrieved trials included 1320 subjects
with a mean age of 39.52± 2.11 years. Most of the studies
did not provide information in regard to ED severity (miss-
ing in 7 studies), BMI of the subjects (missing in 3 studies),
smoking habits (missing in 3 studies), and prevalence of dia-
betes (missing in 1 study).
The I2 in studies assessing serumHcy inmenwith orwith-
out ED was 85.3% (p < 0 0001, (95% CI 73.9%–91.7%)).
Serum Hcy was significantly higher among subjects with
ED compared to controls (SMD 1.00, p < 0 0001, (95%
CI 0.65–1.35)) (Figure 2). A funnel plot and Begg adjusted
rank correlation test (Kendall’s τ: 1.147; p = 0 29) suggested
no publication bias (Figure 3).
Sensitivity analysis was then performed based on preva-
lence of diabetes. Five studies [24–28] had diabetes as an
exclusion factor, whereas 2 included only subjects with dia-
betes [29, 30], one [31] did not report actual prevalence of
diabetes, and another one [32] reported 4.7% of diabetes
among controls and 3.5% among ED patients. The resulting
Table 1: Studies included in the meta-analysis. Data expressed as means± standard deviation.
Study Country Method
Subjects without ED Subjects with ED
N Hcy Age N Hcy Age
Demir et al. [24] Turkey Immunoassay 33 10.7± 1.6 44.5± 4.7 31 16.4± 5.4 55.6± 8.4
Al-Hunayan et al. [29] Kuwait HPLC 97 8.8± 2.6 47.6± 10.1 97 11.2± 3.5 46.6± 9.9
Demir et al. [30] Turkey Immunoassay 30 13.1± 2.5 53.6± 6.5 32 15.5± 6.9 54.2± 7.3
Safarinejad et al. [32] Iran HPLC 228 9.82± 2.35 31.7± 6.6 114 12.29± 2.32 32.2± 6.4
Basar et al. [25] Turkey HPLC 20 10.4± 2.4 38.6± 8.2 28 13.2± 4.3 40.2± 7.5
Matos et al. [31] Brazil HPLC 306 11.09± 4.37 38.6± 13.99 57 11.66± 4.61 54.1± 12.83
Yan et al. [26] China Immunoassay 66 7.98± 2.8 29.41± 4.42 67 11.73± 2.81 29.12± 4.41
Sansone et al. [27] Italy HPLC 31 9.17± 2.32 49.14± 13.63 31 13.61± 3.55 52.83± 11.89
Zhang et al. [28] China Immunoassay 20 9.6± 2.6 32.8± 7.8 32 18.94± 6.19 34.08± 11.99
Study
Random effects model 489 831 1.00 100.0%[0.65; 1.35]
[0.90; 2.00] 10.3%
12.5%
10.7%
12.9%
9.8%
12.6%
11.8%
10.1%
9.2%
[0.49; 1.07]
[−0.05; 0.96]
[0.82; 1.29]
[0.18; 1.36]
[−0.15; 1.71]
[0.96; 1.71]
[0.92; 2.48]
[1.16; 2.48]
Total Mean SD Total Mean SD
ED No ED Standardized mean
difference SMD 95% CI Weight
Demir et al., 2006
Demir et al., 2008
Safarinejad et al., 2010
Basar et al., 2013
Matos et al., 2013
Yan et al., 2014
Sansone et al., 2017
Zhang et al., 2017
Al-Hunayan et al., 2008
31 16.40 5.40 1.60
2.60
2.50
2.35
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4.37
2.80
2.32
2.60
33 10.70
8.80
13.10
9.82
10.40
11.09
7.98
9.17
9.60
97
30
228
20
306
66
31
20
3.50
6.90
2.23
4.30
4.61
2.81
3.55
6.19
11.20
15.50
12.29
13.20
11.66
11.73
13.61
18.94
97
32
114
28
57
67
31
32
1.45
0.78
0.46
1.06
1.34
1.48
1.82
0.77
0.13
Heterogeneity: /2 = 85.30% 𝜏2 = 0.24, p < 0.0001 −2 −1 0 1 2
Figure 2: Forest plot for the base model.
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forest plot is shown in Figure 4. Association between Hcy
and ED appears steeper in nondiabetic subjects. Indeed,
absence of ED is associated with a SMD of 1.34 (95%
CI 1.08–1.60) in subjects without diabetes, while SMD is
significantly lower in subjects with diabetes (0.68 (95%
CI 0.39–0.97); Q 12.00, p < 0 0025 versus subgroup w/o dia-
betes). Despite remaining higher in the subgroup with
“mixed” prevalence of diabetes, heterogeneity is remarkably
reduced in both other subgroups.
4. Discussion
The results of our meta-analysis suggest that Hcy is signifi-
cantly associated with ED, showing a mean increase of 1.00
standard deviation between controls and ED patients.
Among patients with ED, sensitivity analysis has shown that
when stratified for presence of diabetes, subjects without dia-
betes are more likely to have increased levels of serum Hcy
compared to diabetic subjects; conversely, this association
appears evident in patients with diabetes even for small var-
iation of Hcy, or rather, it could be argued that in diabetic
patients, a small increase of Hcy is enough to negatively
affect erectile function. In fact, the difference between dia-
betic and nondiabetic patients might suggest that in the
presence of comorbidities, small changes in serum Hcy
might negatively be involved in erectile function, based on
the premise that multiple risk factors might act in a synergis-
tic, rather than additive, fashion [33, 34]. This observation
1.51.00.5
0.30
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0.05
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Figure 3: Funnel plot for all studies included in the meta-analysis.
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Figure 4: Forest plot by subgroup.
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seems to be rather counterintuitive, as Hcy is a risk factor for
cardiovascular events, whose prevalence is higher in diabetic
people, and also a sign of metabolic derangement, featured
in diabetes [35]. Indeed, different studies observed higher
serum level of Hcy both in type 1 and in type 2 diabetes mel-
litus [36]. More in detail, serum Hcy level appears to be
higher in patients affected by T1DM suffering with retinop-
athy and/or nephropathy [36]. Interestingly, antidiabetic
treatment may be considered as an important factor
involved in regulation of level of Hcy in diabetic patients
[37]: a recent meta-analysis showed both detrimental and
beneficial effects of several drugs commonly used in meta-
bolic syndrome and in type 2 diabetes mellitus [38].
Although there seems to be no significant effect of antidia-
betic treatments on Hcy levels as a whole (SMD −0.53
(95% CI −1.60 to 0.53)), combination treatment with thiazo-
lidinediones and diguanides or meglitinide and thiazolidine-
diones has shown significant effects on lowering serum Hcy
(SMD −1.67 (95% CI −2.85 to −0.50) and SMD −4.40 (95%
CI −4.94 to −3.86), resp.). Following on, metformin appears
to increase serum Hcy levels decreasing serum B12 and
folate level, although the exact mechanism is not known.
Unexpectedly, the improved sensitivity to insulin associated
with metformin has been associated to an increase in plasma
Hcy [39, 40]; conversely, rosiglitazone as well as pioglitazone
showed interesting properties in lowering serum Hcys level
[37, 41, 42]. It has been suggested that insulin may stop
homocysteine catabolic transformations resulting in an
increase in the amount of homocysteine and its blood level
[43]. Nevertheless, it should be considered that in T2DM
insulin-induced increments of methionine transmethylation,
homocysteine transsulfuration, and clearance were mark-
edly reduced [44]. On the contrary, in T1DM, insulin dep-
rivation brings about an increase in Hcy, whereas insulin
treatment normalized transsulfuration and remethylation
of Hcy, therefore decreasing its serum levels. Furthermore,
in the same study, plasma homocysteine concentrations
were observed to be lower in T1DM compared to healthy
controls [45]. Similarly, in healthy humans, insulin seems
to increase in vivo homocysteine clearance [46].
As previously stated, HHcy is closely associated with
endothelial dysfunction. Studies in animal models have
proven that HHcy markedly inhibits NO formation in rabbit
isolated corpus cavernosum [47]. NO acts as a key regulator
for endothelial function: activation of guanylyl cyclase by NO
leads to increased levels of cyclic GMP (cGMP), which in
turn allow for smooth muscle relaxation in the corpora
cavernosa [48]. High levels of serum Hcy have been associ-
ated with uncoupling of the endothelial NO synthase enzyme
(eNOS), therefore reducing availability of NO while at the
same time increasing production of reactive oxygen species
(ROS). HHcy has also been proven an independent risk fac-
tor for atherosclerosis [49], providing further proof of a caus-
ative role for Hcy in the pathogenesis of ED.
Our study has some limitations, most notably the small
number of studies involved and the lack of a clear definition
of ED. A single study [31] assessed presence of ED by means
of a single question (“How would you describe your ability to
get and keep an erection that is adequate for satisfactory
intercourse?”). The remaining studies used validated ques-
tionnaires: in detail, four studies [24, 25, 30, 32] used the IIEF
and four studies [26–29] used the IIEF-5 [22]. However, most
studies did not report separate measurements of serum Hcy
based on the degree of severity of ED.
5. Conclusions
Results from our meta-analysis suggest that increased levels
of serum Hcy are more often observed in subjects with ED:
based on existing literature on this topic, a causative role
for HHCy as an independent risk factor for ED can be postu-
lated, although confirmation would require interventional
studies aimed to decrease serum Hcy levels considering erec-
tile function as primary outcome. Actually, only in rat model
of HHcy has been observed an improvement in erectile func-
tion after being treated with a demethylation agent [50]. We
also reported significantly higher levels of Hcy in subjects
without diabetes, compared to diabetic men: while we can
assume that this is further proof of a multifactorial pathogen-
esis for ED, it is also a clear indication that future research in
this field should investigate the possible association with
other known risk factors—such as smoking habit and obe-
sity—in order to adequately address the possible effects of
different variates.
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